New Delhi: Following a crackdown on 156 fixed dose combination (FDC) drugs after finding them without therapeutic justification and even unsafe in several cases, a top official in the Central Drugs Standard Control …
New Delhi: A top panel under the Central Drugs Standard Control Organisation (CDSCO) — India’s national regulatory body for pharmaceuticals and medical devices — has recommended regulatory approval to import …
New Delhi: A proposal by the Central Drugs Standard Control Organisation (CDSCO), India’s apex drug regulator, to classify all nicotine replacement therapies (NRT) — treatments aimed at helping people stop the use …
New Delhi: India’s apex drug regulator has asked medical device makers to self-report all adverse events related to their equipment through the Centre’s Materiovigilance Programme of India (MvPI), ThePrint has learnt. …
New Delhi: After a string of adverse events in the last two years, India’s apex drug regulator will from 15 May onwards grant manufacturing licenses for drugs that are banned …
New Delhi: India’s apex drug regulator has come up with new guidelines for sampling of drugs, cosmetics and medical devices amid persistent concerns around the quality of medicines manufactured in the …
New Delhi: India’s apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO), last month instructed drugmakers not to sell a popular fixed dose combination (FDC) medicine, indicated as a …
New Delhi: For the first time in India, defective or adulterated drugs can be recalled even if they reach the market at large. The new mandate is part of the changes …
New Delhi: Global pharmaceutical giants are pushing the Central Drugs Standard Control Organisation (CDSCO) for faster approvals by granting parallel market authorisation that will allow drugs and innovative therapies to …